Home

Pfizer Inc. said Thursday it stopped a late-stage clinical study of its drug Sutent as a treatment for liver cancer. Pfizer said patients who were treated with Sutent were not surviving as long as patients who were treated with another drug, Bayer Healthcare ...

Whenever I use the bathroom at work, I put down one of those paper seats on top of the bowl. Is this actually protecting me from anything or is it just there for mental comforts? And what kinds of diseases or sickness can you actually catch from a toilet seat? — J. Kahn, Queens, New York I actually researched this question ...

BEIJING (Reuters) - Imprisoned Chinese AIDS activist Hu Jia is suffering from a serious disease, possibly liver cancer, his wife said on Thursday after making a formal appeal to security forces to release him on medical parole. Hu's mother saw a suspected diagnosis of liver cancer on a consent form she was asked to sign when he was taken to ...

LONDON (Reuters) - A compound found in the common curry spice turmeric appears to delay the liver damage that eventually causes cirrhosis, scientists said on Wednesday. In a study published in Gut, a British Medical Journal title, Austrian scientists found that feeding the compound curcumin to mice reduced the types of inflammation that can cause liver cell damage, blockage and scarring ...

US scientists have discovered a way to block replication of the hepatitis C virus, potentially leading to better treatment for the top cause of liver cancer in the United States, a study said Wednesday. In vitro experiments identified a protein that is essential to the reproductive cycle of the hepatitis C virus (HCV), the researchers said. An altered synthetic version ...

WASHINGTON (Reuters) - U.S. scientists have identified a new class of drugs that appear to block the hepatitis C virus from replicating in laboratory experiments, researchers said on Wednesday. The team discovered activity within a key protein of the hepatitis C virus (HCV) essential for the virus to reproduce, they reported in the online journal Science Translational Medicine. The researchers ...

In a story Jan. 11 about Vertex Pharmaceuticals Inc. and its hepatitis C drug, The Associated Press misstated when the company will seek regulatory approval for the drug. Approval will be requested in the second half of 2010, not 2009.

In a story Jan. 11 about Vertex Pharmaceuticals Inc. and its hepatitis C drug, The Associated Press misstated when the company will seek regulatory approval for the drug. Approval will be requested in the second half of 2010, not 2009.

Biotechnology company Vertex Pharmaceuticals Inc. said Monday it plans to seek regulatory approval of the experimental hepatitis C drug telaprevir as scheduled during the second half of 2009. Telaprevir is one of several potential hepatitis C treatments in development. If approved, it could face competition ...

Shares of Achillion Pharmaceuticals Inc. surged Wednesday after the company said its hepatitis C drug candidate showed positive "proof-of-concept" results, while meeting safety and tolerability goals in an early-stage study. The stock gained $1.12, or 52 percent, to $3.27 in afternoon trading. Shares reached $3.89 earlier ...